Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

RU58841, combined with 5% minoxidil, helped reduce acne and hair loss. Users discussed using RU58841 cream for acne and shared experiences with other treatments like finasteride and dutasteride.

The conversation is about a user's hair loss treatment progress using minoxidil, finasteride, and red light therapy. The user plans to continue using a combination of finasteride, minoxidil, and biotin, and uses a FIVORRA red light therapy hat.

Follistatin, known for inhibiting myostatin and promoting muscle growth in mice, is being discussed as a potential treatment for hair loss. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

RU58841's effectiveness from rudirect is questioned. Users discuss experiences with RU58841, Minoxidil, and finasteride for hair loss treatment.

Clascoterone (Breezula) shows a potential 500% increase in hair growth, possibly outperforming minoxidil and finasteride. It is in advanced trials, with hopes for FDA approval, but cost and side effects are concerns.

The user discusses using Follics FR5, FR10, and FR15, which combine Minoxidil, Adenosine, Procapil, Azelaic acid, and Procyanidin B2, to address hair loss. They have previously used Minoxidil, Finasteride, and Dutasteride with varying success.

Breezula is seen as a potential future treatment for hair loss, but its release is uncertain and current data is limited. Other treatments like GT20026 and pyrilutamide are discussed, but skepticism remains about their effectiveness compared to established options like finasteride and minoxidil.

Breezula (clascoterone) initially performed better than finasteride for hair loss but then effectiveness decreased almost back to baseline after 6 months, raising questions about its strength.

The user has been using dutasteride for 7 months with no improvement in hair loss and is considering switching to finasteride, while also using oral minoxidil. Another user shared their positive experience switching from dutasteride to finasteride, noting less shedding and improved hair condition.

RU58841 is discussed as a hair loss treatment, with concerns about potential heart risks and systemic side effects. Some users suggest trying FDA-approved treatments like finasteride first, while others debate the safety and cost-effectiveness of RU58841.

A YouTuber known for skepticism is hinting at a promising new hair regrowth treatment. The treatment details are undisclosed, but it is not related to known substances like RU58841.

Breezula shows promising results for hair loss, with one trial showing a 539% improvement and another 168%, but lacks combination data with treatments like minoxidil or dutasteride. Its mechanism differs from finasteride, potentially offering fewer side effects by blocking receptors locally at the follicle.

PP405 shows promise for reactivating hair follicles, with potential maintenance using 5AR inhibitors. Current treatments like Minoxidil and finasteride are effective but have limitations, and there is hope for more effective solutions in the future.

The user has been using 1mg finasteride, 2% ketoconazole shampoo, vitamins, and growth shampoo for 7.5 months to treat hair loss and is considering switching to 0.5 mg dutasteride due to slight recession and persistent symptoms. Another user commented that the user's temples appear to have improved, especially in the latest photo.

A treatment containing Wnt and Follistatin was found to be safe and effective for hair regrowth in a Phase 1 clinical trial. Specific treatments discussed include Minoxidil, Finasteride, and RU58841.

A 21-year-old experienced significant hair regrowth using oral finasteride for 7 months, initially with minoxidil but later stopped due to inconvenience. He had no major side effects, except a temporary increase in sex drive, and plans to continue finasteride.

AMP-303 and AMP-601 are new hair loss treatments targeting dermal papilla cells, with AMP-303 showing early efficacy in transitioning vellus hairs to terminal hairs after one injection. Further clinical trials are planned, and these treatments are seen as promising due to their biologic approach and less frequent application compared to daily treatments.

Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.

Actifolic RU-58841 powder and GhK-Cu peptide were tested and found to be accurate. The user is satisfied with the product's authenticity for hair loss treatment.

GT20029 shows promise as a topical treatment for hair loss, potentially replacing finasteride for some due to its low systemic exposure and ability to degrade androgen receptors. However, skepticism remains about its long-term efficacy and availability, with some users expressing doubt about new treatments consistently failing to reach the market.

Extended-release oral minoxidil (VDPHL01) shows promising results for hair growth with improved safety, achieving significant hair count increases and minimal side effects compared to placebo. The treatment is designed to maintain effective concentrations while reducing side effects, making it a safer option for those who cannot tolerate standard minoxidil.

A user is experiencing hairline recession and has started using RU58841, applying it to the temples. They are seeking advice on the appropriate dosage for this specific area.

The conversation discusses the application of RU58841 for hair loss, with the user applying 1.75 mg at 5% concentration for half an hour daily. The user mentions managing seborrheic dermatitis while using this treatment.

Finasteride is helping regrow hair in previously thinning areas, and the user plans to add minoxidil to enhance results. The user is considering increasing the finasteride dose to 1mg daily for better outcomes.

Hair loss may be linked to the GPR133 receptor, independent of the androgen receptor pathway. Treatments like finasteride, dutasteride, minoxidil, RU58841, and KX-826 show varying results, with hair loss persisting due to high testosterone and GPR133's role.

The conversation is about using micro needling and PTD-DBM for hair loss treatment. The user applies PTD-DBM drops on weekdays and performs micro needling weekly.

Reducing the dose of RU58841 from 25mg to 7.5mg topically helped minimize heart palpitations. Users discussed the cardiac effects of RU58841 and minoxidil, noting that no treatment is completely free of side effects.

Hair loss involves more than just DHT, with genetic factors like TRPS affecting hair follicles. Treatments such as Amplifica's AMP-601 and AMP-303 target stem cells for potential hair growth solutions.

Significant hair regrowth was achieved using EssenGen 6-Plus with 6% minoxidil and 0.05% finasteride, along with Nizoral shampoo, over 12 weeks. No side effects were experienced, highlighting the benefits of a low dose.

Zohran Mamdani is using oral minoxidil for hair loss. There is discussion about the importance of using a DHT blocker like finasteride alongside minoxidil.